GemVax & KAEL said a research article that confirms the potential of GV1001 as a therapy to treat RCC (Renal Cell Carcinoma) was published in the online edition of international journal “Urology” last Wednesday.
A research team led by Professor Lee Ji-youl이지열 of the Department of Urology at the Catholic University, investigated the effects of GV1001 on cell viability and apoptosis in RCC cells in vitro using cell viability test, FACS (Fluorescence-activated cell sorting) and Tunnel assay and evaluated the effects of GV1001 in angiogenesis of the RCC.
The team also confirmed the anticancer effects of GV1001 in vivo in an RCC xenograft mouse model experiment.
As a result, the team demonstrated that GV1001 reduced cell viability and induced apoptosis in the RCC cells and also confirmed that GV1001 induced apoptosis by suppressing angiogenesis through decreased expression of HIF-1α, VEGF, and PDGF in the xenograft mouse model.
“This is the first study to show that GV1001 exerted anti-cancer effects on the RCC both in vitro and in vivo,” Professor Lee said. “We will further investigate the potential of GV1001 as a novel drug for primary and metastatic RCC through additional studies in the future.”
Song Hyoung-gon송형곤, CEO of GemVax & KAEL, said, “The phase 3 clinical trial for pancreatic cancer in Korea is going smoothly. We will do our best to establish GV1001 as a locally developed best anti-cancer drug by researching another type of cancers including the RCC based on the result of this study.”
<© Korea Biomedical Review, All rights reserved.>